Clinical Orthopaedics and Related Research ®

A Publication of The Association of Bone and Joint Surgeons ®

Tumor 246 articles

Articles

The Phosphaturic Mesenchymal Tumor: Why is Definitive Diagnosis and Curative Surgery Often Delayed?

Cameron K. Ledford MD, Nicole A. Zelenski BS, Diana M. Cardona MD, Brian E. Brigman MD, PhD, William C. Eward DVM, MD

Tumor-induced osteomalacia is a paraneoplastic syndrome resulting in renal phosphate wasting and decreased bone mineralization. Phosphaturic mesenchymal tumors represent a rare etiology of tumor-induced osteomalacia. Nonspecific symptoms of fatigue, bone pain, and musculoskeletal weakness make the diagnosis elusive and lead to a delay in surgical treatment.

Image Guided Core Needle Biopsy of Musculoskeletal Lesions: Are Nondiagnostic Results Clinically Useful?

Manjiri M. Didolkar MD, MS, Megan E. Anderson MD, Mary G. Hochman MD, MBA, Julia G. Rissmiller MD, Jeffrey D. Goldsmith MD, Mark G. Gebhardt MD, Jim S. Wu MD

The clinical utility of nondiagnostic core needle biopsies is not fully understood. Understanding the clinical and radiologic factors associated with nondiagnostic core needle biopsies may help determine the utility of these nondiagnostic biopsies and guide clinical decision making.

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Benjamin J. Miller MD, MS, Charles F. Lynch MD, MS, PhD, Joseph A. Buckwalter MD, MS

Conditional survival is a measure of the risk of mortality given that a patient has survived a defined period of time. These estimates are clinically helpful, but have not been reported previously for osteosarcoma or Ewing’s sarcoma.

Knee Pain in a 9-year-old Girl

Eric R. Henderson MD, Rebecca A. Pohlmann MD, Lisa A. Teot MD, Mark C. Gebhardt MD

Silver Negative Pressure Dressing With Vacuum-assisted Closure of Massive Pelvic and Extremity Wounds

Herrick J. Siegel MD, Diego F. Herrera MD, Jason Gay CRNFA

Massive soft tissue loss involving the pelvis and extremities from trauma, infections, and tumors remains a challenging and debilitating problem. Although vacuum-assisted closure (VAC) technology is effective in the management of soft tissue loss, the adjunct of a silver dressing in the setting of massive wounds has not been as well tested.

Complications of Cemented Long-stem Hip Arthroplasty in Metastatic Bone Disease Revisited

Shawn L. Price MD, M. Aabid Farukhi BA, Kevin B. Jones MD, Stephen K. Aoki MD, R. Lor Randall MD, FACS

The literature suggests that a cemented long-stem femoral arthroplasty is associated with increased intraoperative and perioperative risks. Embolic events may precipitate cardiopulmonary complications and even death; by contrast, others have reported that the use of a cemented long-stem femoral arthroplasty in patients with metastatic bone disease is a safe procedure.

Chick Embryo Extract Demethylates Tumor Suppressor Genes in Osteosarcoma Cells

Xiaodong Mu PhD, Bolat Sultankulov BS, Riddhima Agarwal, Adel Mahjoub, Trevor Schott BS, Nicholas Greco MD, Johnny Huard PhD, Kurt Weiss MD

Epigenetics is the study of changes in gene expression or cellular phenotype caused by mechanisms other than changes in the underlying DNA sequence. It is widely accepted that cancer has genetic and epigenetic origins. The idea of epigenetic reprogramming of cancer cells by an embryonic microenvironment possesses potential interest from the prospect of both basic science and potential therapeutic strategies. Chick embryo extract (CEE) has been used for the successful expansion of many specific stem cells and has demonstrated the ability to facilitate DNA demethylation.

How Long Should We Follow Patients With Soft Tissue Sarcomas?

Chigusa Sawamura MD, MPH, Seiichi Matsumoto MD, PhD, Takashi Shimoji MD, PhD, Atsushi Okawa MD, PhD, Keisuke Ae MD, PhD

Guidelines suggest that followup for low-grade soft tissue sarcomas should be every 3 to 6 months for 2 to 3 years and then annually, and for high-grade sarcomas every 3 to 6 months for 2 to 5 years, then every 6 months for the next 2 years, and then annually. However, there is only very limited evidence to support these strategies.

Incidence and Risk Factors for Pulmonary Embolism After Primary Musculoskeletal Tumor Surgery

Koichi Ogura MD, Hideo Yasunaga MD, PhD, Hiromasa Horiguchi PhD, Kazuhiko Ohe MD, PhD, Hirotaka Kawano MD, PhD

Limited information is available regarding the incidence, risk factors, and optimal prophylaxis in orthopaedic oncology patients, although malignancy and major orthopaedic surgery are associated with an increased pulmonary embolism (PE) risk.

Radiation Therapy Is Associated With Fewer Recurrences in Mesenchymal Chondrosarcoma

Satoshi Kawaguchi MD, Israel Weiss MD, Patrick P. Lin MD, Winston W. Huh MD, Valerae O. Lewis MD

Mesenchymal chondrosarcoma (MSC) is a rare variant of chondrosarcoma. Because of the rarity of the disease, most studies only contain a small number of patients and thus the prognostic variables and role of adjuvant therapies remain controversial.